Merck to acquire Prometheus Biosciences for $10.8B

Merck & Co. is acquiring Prometheus Biosciences in a $10.8 billion deal. All the shares of Prometheus Biosciences will be acquired by a subsidiary of Merck for $200 per share.. The deal gives Merck promising immune disease treatments. The acquisition is subject to Prometheus Biosciences…#merckco #merck #prometheus #robertmdavis #keytruda #sandiego #crohn #imagobiosciences
Source: Reuters: Health - Category: Consumer Health News Source Type: news